P/E ratio for GSK plc (GSK)

P/E ratio history for GSK plc from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Novartis NVS	31.2	74.06%	🇨🇭 Switzerland
Pfizer PFE	38.5	114.72%	🇺🇸 USA
Sanofi SNY	25.3	41.17%	🇫🇷 France
Merck MRK	150	736.59%	🇺🇸 USA
AstraZeneca AZN	28.4	58.28%	🇬🇧 UK
Teva Pharmaceutical Industries TEVA	68.2	280.78%	🇮🇱 Israel
Dynavax Technologies DVAX	-48.4	-370.41%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.